The pancreatic effects of the "twincretin" tirzepatide (Mounjaro) appear to depend at least as much on the drug's agonist activity on the glucose-dependent insulinotropic polypeptide (GIP) receptor as ...

In transition-age patients with childhood-onset growth hormone deficiency (GHD), peak growth hormone (GH) response to the glucagon stimulation test (GST) appeared to be influenced more by the severity ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

Eli Lilly, a U.S. pharmaceutical company, announced that its next-generation obesity treatment under development achieved ...

New findings raise the possibility of promising therapeutic strategies for the management of hypoglycemia in type 1 diabetes patients. Study: Loss of electrical β-cell to δ-cell coupling underlies ...

Results from a late-stage trial of Boehringer Ingelheim and Zealand Pharma's GLP-1 and glucagon agonist drug survodutide suggest it is on track to challenge Novo Nordisk and Eli Lilly, which currently ...